Project Grant R01AA032748
Award Date 8/11/26
Completion Date 4/30/31
Dollars Obligated $663K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health within the Department of Health and Human Services, awarded $682,736 to Beth Israel Deaconess Medical Center, Inc. on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate myeloid-derived suppressor cells (MDSCs) in alcohol-associated steatohepatitis. The award funds research characterizing MDSC phenotypes and immunoregulatory capacity in alcohol-associated hepatitis...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $1.321 million on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to investigate ITPR3 and aberrant mitochondrial calcium signaling in alcoholic hepatitis. The project examines how altered mitochondrial calcium signaling contributes to the development of alcohol-associated hepatitis (AAH), a severe complication of alcohol-associated liver disease with short-term mortality ranging from 20 to 50...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $2,072,751 under the Alcohol Research Programs (CFDA 93.273) on September 15, 2025. The recipient is conducting research into innate immune dysregulation in alcohol-associated liver disease, with focus on neutrophil heterogeneity and dysfunction in alcohol-associated hepatitis. The work characterizes transcriptomic profiles and functional roles of neutrophil populations—specifically...
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Health Science Center at San Antonio $664,792 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate post-transcriptional mechanisms and cellular senescence in age-related alcoholic liver disease. The research targets dysregulated nutrient sensing as a hallmark of aging that drives hepatic steatosis progression toward cirrhosis and hepatocellular carcinoma. The recipient will...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $456,096 under Project Grant R21AA031889 on September 10, 2025, to explore the role of hepatocyte inflammasome in alcoholic liver disease (AALD). The research investigates how caspase-1, a component of the inflammasome pathway, influences AALD pathophysiology in hepatocytes. The project employs liver-specific genetic deletion models using albumin-cre mice, bulk RNA sequencing, proteomic analysis, and in vitro...
- Federal Grant Award Summary Yale University received a $440,566 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 16, 2025, with a completion date of August 31, 2027. The grant funds research to advance treatment of alcohol-associated liver disease (ALD) through precision targeting of methyltransferase-like (METTL) protein family members, specifically METTL7A. The project will deliver mechanistic...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of Columbia University in the City of New York $2,359,200 on July 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the regulation of hepatocyte functions by hepatic stellate cells in steatotic liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated fatty liver disease, and mixed forms. The research characterizes an R-spondin 3-mediated hepatic stellate cell...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $596,476 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the role of acute phase response signaling in alcohol-associated liver disease resolution. The project, awarded as a Project Grant (R01AA032810), funds research examining how hepatocytes direct a resolution program following alcohol cessation, producing signals that alter liver...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Illinois $110,228 on November 10, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct time-resolved, single-nucleus multiomics research on HMGB1-mediated mechanisms of alcohol-associated liver disease progression and recovery. The project will deconvolute bulk RNA-sequencing datasets from human alcohol-associated liver disease samples using human single-cell RNA-sequencing references to quantify...
- The National Institute on Alcohol Abuse and Alcoholism awarded Loyola University of Chicago Health Sciences Campus $470,066 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct basic research on the molecular mechanisms by which ABL kinase 2 (ABL2) contributes to alcohol-associated liver disease pathogenesis. The research will investigate three specific areas: the molecular mechanisms by which ABL2 promotes alcohol-induced steatosis; the role of ABL kinases in...